Azitra (AZTR) Stock Price, News & Analysis

Company Overview

Azitra, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutic products for dermatological conditions. The company uses microbiome science and genetic engineering to develop beneficial bacteria designed for topical application to the skin.

Azitra’s research programs have focused on conditions including atopic dermatitis, acne vulgaris and other skin disorders associated with impaired barrier function or microbial imbalance. Its pipeline has included engineered strains of skin-associated bacteria intended to deliver therapeutic proteins or other biological effects directly to affected areas.

The company was founded in 2014 and is based in New Haven, Connecticut. Its development programs are primarily aimed at the dermatology market, although detailed information about commercial operations, geographic reach and current leadership may change as the company advances its pipeline.

Key Stats

• Today's Range: $0.05 to $0.12
• 50-Day Range: $0.07 to $0.19
• 52-Week Range: $0.05 to $1.09
• Volume: 2.67 million shs
• Average Volume: 746,577 shs
• Market Capitalization: $4.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Azitra Stock Analysis - MarketRank™

Azitra scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Azitra.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Azitra are expected to grow in the coming year, from ($0.20) to ($0.06) per share.

Price to Book Value per Share Ratio

Azitra has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.40% of the float of Azitra has been sold short.

Short Interest Ratio / Days to Cover

Azitra has a short interest ratio ("days to cover") of 0.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Azitra has recently decreased by 65.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azitra does not currently pay a dividend.

Dividend Growth

Azitra does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Azitra has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Azitra this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for AZTR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azitra insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.28% of the stock of Azitra is held by insiders.

Percentage Held by Institutions

11.16% of the stock of Azitra is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:AZTR
• CIK: 1701478
• Web: azitrainc.com
• Phone: (203) 489-0183
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -205.46%
• Return on Assets: -161.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.86
• Quick Ratio: 4.86

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 425.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 60,600,000
• Free Float: 60,434,000
• Market Cap: $4.25 million
• Optionable: Not Optionable
• Beta: -1.05